Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
Rev. Soc. Bras. Med. Trop
; 52: e20180211, 2019. tab, graf
Article
em En
| LILACS
| ID: biblio-1003136
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.
Palavras-chave
Texto completo:
1
Bases de dados:
LILACS
Assunto principal:
Leishmaniose Cutânea
/
Antimoniato de Meglumina
/
Antiprotozoários
Limite:
Adult
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Assunto da revista:
MEDICINA TROPICAL
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Colômbia